Psych MEQs / SAQs · Psychopharmacology — mood stabilisers
Mood stabiliser choice, lithium monitoring and pregnancy hierarchy (MEQ)
FRANZCP-style MEQ on mood stabiliser selection, lithium monitoring, valproate pregnancy hierarchy, lamotrigine titration, and lithium toxicity prevention.
On this page & tools
Target exams
Model answer
Reveal model answer
(i) Preferred strategy and evidence. For bipolar I maintenance after recurrent mania, lithium is the preferred long-term cornerstone when monitoring is feasible: BALANCE showed lithium monotherapy superior to valproate monotherapy for relapse prevention, with combination also effective; lithium also carries an anti-suicide evidence signal. Shared decision covers benefits, monitoring burden, and future pregnancy planning rather than marketing “strength.” Continue or taper olanzapine based on residual symptoms and metabolic risk once a stabiliser is established.[1][2]
(ii) Lithium practicalities. Baseline: eGFR/creatinine, U&E, TFT, calcium, pregnancy test, weight, ECG if indicated. Educate on hydration and interacting drugs. Levels are 12-hour troughs at steady state after initiation/dose change. ISBD/IGSLI-informed maintenance targets commonly around 0.6–0.8 mmol/L for many adults, individualised. Recheck early, then periodically with renal/thyroid/calcium surveillance.[3][7]
(iii) Valproate hierarchy. Do not recommend valproate as routine maintenance given pregnancy potential. EURAP shows high, dose-dependent major malformation risk; Meador NEAD shows adverse cognitive outcomes after fetal valproate. If any discussion of valproate ever occurs under exceptional frameworks, document highly effective contraception, teratogen counselling, and specialist oversight — her inconsistent contraception is a hard stop for casual use.[4][5]
(iv) Lamotrigine. Best for depression-pole prevention/maintenance rather than rapid antimanic rescue. Slow titration (classic 25 mg then 50 mg fortnightly skeleton toward ~200 mg as tolerated); slower with valproate; stop for concerning rash.[6][8]
(v) Interactions and illness. NSAIDs, ACE inhibitors/ARBs, and thiazides raise lithium. In gastroenteritis/dehydration: hold lithium, rehydrate, urgent level and renal panel when unwell, restart only when eating/drinking and levels safe — prevent chronic accumulation toxicity.[7]
Common errors
- Calling valproate “stronger” than lithium for maintenance despite BALANCE monotherapy result.[1]
- Ordering a random lithium level one hour post-dose and treating it as a trough.[3]
- Omitting pregnancy-prevention hierarchy when the patient has inconsistent contraception.[4][5]
- Rapid lamotrigine loading on valproate.[8]
- Continuing lithium through severe dehydration without holding and rechecking.[7]
References
- [1]BALANCE investigators and collaborators, Geddes JR, Goodwin GM, et al. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial Lancet, 2010.PMID 20092882
- [2]Cipriani A, Hawton K, Stockton S, et al. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis BMJ, 2013.PMID 23814104
- [3]Nolen WA, Licht RW, Young AH, et al. What is the optimal serum level for lithium in the maintenance treatment of bipolar disorder? A systematic review and recommendations from the ISBD/IGSLI Task Force on treatment with lithium Bipolar Disord, 2019.PMID 31112628
- [4]Tomson T, Battino D, Bonizzoni E, et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry Lancet Neurol, 2011.PMID 21652013
- [5]Meador KJ, Baker GA, Browning N, et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs N Engl J Med, 2009.PMID 19369666
- [6]Goodwin GM, Bowden CL, Calabrese JR, et al. A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder J Clin Psychiatry, 2004.PMID 15096085
- [7]Gitlin M Lithium side effects and toxicity: prevalence and management strategies Int J Bipolar Disord, 2016.PMID 27900734
- [8]Calabrese JR, Bowden CL, Sachs GS, et al. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group J Clin Psychiatry, 1999.PMID 10084633